Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice.
about
Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry diseaseLong-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cellsSubstrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry diseaseThe development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases.A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis.Depletion of globosides and isoglobosides fully reverts the morphologic phenotype of Fabry diseaseAdeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease.Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.Fabry disease: recent advances in enzyme replacement therapy.Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice.Efficient uptake of recombinant α-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneysCellular and tissue distribution of intravenously administered agalsidase alfa.Genomic abnormalities of the murine model of Fabry disease after disease-related perturbation, a systems biology approach.Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice.Sphingolipids and membrane biology as determined from genetic models.Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease.Spontaneous Accumulation of Globotriaosylceramide (Gb3) in Proximal Renal Tubules in an ICR MouseGlycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion.Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors.Fabry disease: case report with emphasis on enzyme replacement therapy and possible future therapeutic options.Changes in Ionic Conductance Signature of Nociceptive Neurons Underlying Fabry Disease Phenotype.Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease.Fabry disease: renal sphingolipid distribution in the α-Gal A knockout mouse model by mass spectrometric and immunohistochemical imaging.Neuropathic pain in a Fabry disease rat model.Medullary thick ascending limb impairment in the GlatmTg(CAG-A4GALT) Fabry model mice.Fabry disease
P2860
Q28506514-6D26F94F-E4F6-47F9-AD47-65F96B67D134Q28507358-CB5230CF-A675-4FBD-A155-6179005DCB02Q28748170-CCBA6260-0BB0-4A37-91E8-43F45A3A5F2CQ33825097-B4E15797-187A-4934-89A1-9B0DF4A6CD95Q34159448-3B4E69D8-0EA3-440E-A16D-658E5A2E4549Q34294988-85E0CA3E-7247-4C0F-808D-A4E91683EC3CQ34483749-13A75981-5638-4440-A724-B4586A7E47B1Q34541244-2AB6F6CB-C0BA-4F1C-B2CC-DB8AC7D16C28Q34614418-EB83B837-FA7D-47BF-8A83-BB7EF9192359Q34974879-392C25B8-49C2-431F-8007-C8E0E99842FCQ35152240-2B09DA57-81C3-4163-A09A-85F7C1529F25Q35719001-A40F5F17-5285-4028-9856-506D66695307Q35728693-D8E7E2AE-5B2B-41B8-9A23-29449D96A131Q35768834-E2105111-D48E-48F6-BD3B-68EA769FF871Q35867633-8FA30DA8-999F-4C7B-B795-677D4B5ED448Q36087322-2DE032EC-2A9F-4937-9828-37217FBB870CQ36459028-5F604DFA-0C56-4A8E-8F97-4D4BEDCEDCD0Q37417886-25208466-8E96-4B20-96D4-0FEA11AA396CQ37579380-5048B3F3-C8AD-456A-87C6-D9054CFBECDAQ37591813-D47D32DB-10DE-4637-8B59-3C238D78D4FFQ37695619-352ABAE1-79C8-4EFB-BD8A-5DF0BB5A5A37Q40197647-3E8F8684-75B3-4131-96DA-D349E70F0B4BQ41013852-54A2BAE1-3D77-496E-9043-CBE8821BDBA0Q45869564-0A47C8D8-1602-4347-93AA-675999F10914Q46794267-6BCE4E7D-EC53-4866-9637-DC980D3BC186Q52347263-2FA6E0A0-3BAE-46B4-9236-F4DB92105574Q52725758-93659505-98F5-45D5-8121-6093D3F69E49Q56905945-037CA6F1-DF17-478E-BB61-93B755072187
P2860
Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 1999
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Aging accentuates and bone mar ...... defects in Fabry disease mice.
@en
Aging accentuates and bone mar ...... defects in Fabry disease mice.
@nl
type
label
Aging accentuates and bone mar ...... defects in Fabry disease mice.
@en
Aging accentuates and bone mar ...... defects in Fabry disease mice.
@nl
prefLabel
Aging accentuates and bone mar ...... defects in Fabry disease mice.
@en
Aging accentuates and bone mar ...... defects in Fabry disease mice.
@nl
P2093
P2860
P356
P1476
Aging accentuates and bone mar ...... defects in Fabry disease mice.
@en
P2093
Kulkarni AB
Schiffmann R
Tao-Cheng JH
P2860
P304
P356
10.1073/PNAS.96.11.6423
P407
P577
1999-05-01T00:00:00Z